NeuroDerm

About

Headcount over time

Offices

Q&A

What is NeuroDerm's primary focus?

NeuroDerm is an R&D company that develops drug-device combination solutions for central nervous system disorders, with a focus on improving patient quality of life.

What is NeuroDerm's flagship product?

NeuroDerm's flagship product is ND0612, which is in late-stage development for Parkinson's disease patients experiencing motor fluctuations. It integrates a proprietary levodopa/carbidopa formulation with a delivery system and digital solutions.

When was NeuroDerm acquired and by whom?

NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation in July 2017 for $1.1 billion in cash.

What was the outcome of NeuroDerm's pivotal Phase III BouNDless trial for ND0612?

In January 2023, NeuroDerm announced highly positive results from its pivotal Phase III BouNDless trial evaluating ND0612 in Parkinson's disease patients with motor fluctuations.

When did NeuroDerm initiate a Phase 3 clinical trial for ND0612 in the United States?

In August 2019, NeuroDerm initiated a Phase 3 clinical trial in the United States to evaluate continuous subcutaneous carbidopa/levodopa (ND0612) for Parkinson's disease with motor fluctuations.

How many employees does NeuroDerm currently have?

NeuroDerm has 51–200 employees.

What was NeuroDerm's last recorded funding round before its acquisition?

NeuroDerm had a Public Offering in December 2016, raising $75,000,000.

When was NeuroDerm founded?

NeuroDerm was founded in March 2003.

Team · 11

Kengo Isshiki

CEO

Uri David

CTO

Tami Yardeni

EVP Clinical Development

Karin Baer

VP Quality

Lilach Shmueli-Dayan

VP Finance

Ofer Ekbali

VP Operations & Interim VP Pharmaceutical Development

Ziva Mesika

VP Regulatory Affairs

Adrian Gilbert

VP Pharmaceutical Development

Toshifumi Tada

Chairperson of the Board of Directors

Junya Namba

Board of Directors

Kenji Taguchi

Board of Directors

Sectors & technology

Highlights

Tags